Sulforaphane is Synergistic with CB‐5083 and Inhibits Colony Formation of CB‐5083‐Resistant HCT116 Cells

Human p97 is a potential drug target in oncology. Mutation‐driven drug resistance is an obstacle to the long‐term efficacy of targeted therapy. We found that the ATPase activity for one of the CB‐5083‐resistant p97 mutants was reduced, which also attenuated the degradation of K48 ubiquitinated proteins in cells. To understand how p97 mutant cells with significantly reduced ATPase activity can still grow, we discovered reduced levels of CHOP and NF‐κB activation in the p97 mutant cells and these cellular changes can potentially protect HCT116 cells from death due to lowered p97 activity. In addition, the NF‐kB inhibitor Sulforaphane reduces proliferation of CB‐5083 resistant cells and acts synergistically with CB‐5083 to block proliferation of the parental HCT116 cells. The combination of Sulforaphane and CB‐5083 may be a useful treatment strategy to combat CB‐5083 resistance.

• Publication year

  2022

• Venue

  ChemMedChem

• Publication date

  2022-04-22

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/cmdc.202200030PMID 35451199
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Targeting acute myeloid leukemia dependency on VCP-mediated DNA repair through a selective second-generation small-molecule inhibitor

  2021cited by this paper
• A p97/Valosin-Containing Protein Inhibitor Drug CB-5083 Has a Potent but Reversible Off-Target Effect on Phosphodiesterase-6

  2021cited by this paper
• High-dose ascorbic acid synergizes with anti-PD1 in a lymphoma mouse model

  2020cited by this paper
• Autosomal dominant VCP hypomorph mutation impairs disaggregation of PHF-tau

  2020cited by this paper
• Allosteric p97 Inhibitors Can Overcome Resistance to ATP‐Competitive p97 Inhibitors for Potential Anticancer Therapy

  2020cited by this paper
• Sulforaphane as an anticancer molecule: mechanisms of action, synergistic effects, enhancement of drug safety, and delivery systems

  2020cited by this paper
• Anti-Inflammatory Effect of Sulforaphane on LPS-Activated Microglia Potentially through JNK/AP-1/NF-κB Inhibition and Nrf2/HO-1 Activation

  2019cited by this paper
• Combination cisplatin and sulforaphane treatment reduces proliferation, invasion, and tumor formation in epidermal squamous cell carcinoma

  2018cited by this paper
• Structural Basis of p97 Inhibition by the Site-Selective Anticancer Compound CB-5083

  2018cited by this paper
• Role of the NFκB-signaling pathway in cancer

  2018cited by this paper
• SynergyFinder: a web application for analyzing drug combination dose–response matrix data

  2017cited by this paper
• Structure and Function of p97 and Pex1/6 Type II AAA+ Complexes

  2017cited by this paper
• Specific mutations in the D1–D2 linker region of VCP/p97 enhance ATPase activity and confer resistance to VCP inhibitors

  2017cited by this paper
• A Mighty “Protein Extractor” of the Cell: Structure and Function of the p97/CDC48 ATPase

  2017cited by this paper
• Ubiquitin- and ATP-dependent unfoldase activity of P97/VCP•NPLOC4•UFD1L is enhanced by a mutation that causes multisystem proteinopathy

  2017cited by this paper
• Targeting metabolism and survival in chronic lymphocytic leukemia and Richter syndrome cells by a novel NF-κB inhibitor

  2017cited by this paper
• Canonical NF‐κB signaling in hepatocytes acts as a tumor‐suppressor in hepatitis B virus surface antigen‐driven hepatocellular carcinoma by controlling the unfolded protein response

  2016cited by this paper
• p97 Composition Changes Caused by Allosteric Inhibition Are Suppressed by an On-Target Mechanism that Increases the Enzyme's ATPase Activity.

  2016cited by this paper
• Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells

  2016cited by this paper
• Personalized Preclinical Trials in BRAF Inhibitor–Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies

  2015cited by this paper
• p97/VCP promotes Cullin‐RING‐ubiquitin‐ligase/proteasome‐dependent degradation of IκBα and the preceding liberation of RelA from ubiquitinated IκBα

  2015cited by this paper
• Non-genetic cancer cell plasticity and therapy-induced stemness in tumour relapse: ‘What does not kill me strengthens me'

  2015cited by this paper
• Targeting the AAA ATPase p97 as an Approach to Treat Cancer through Disruption of Protein Homeostasis.

  2015cited by this paper
• Inhibitors of the AAA+ Chaperone p97

  2015cited by this paper
• Drug Resistance in Cancer: An Overview

  2014cited by this paper
• The Synergistic Biologic Activity of Oleanolic and Ursolic Acids in Complex with Hydroxypropyl-γ-Cyclodextrin

  2014cited by this paper
• NF-κB, an Active Player in Human Cancers

  2014cited by this paper
• Delivery of an enzyme-IGFII fusion protein to the mouse brain is therapeutic for mucopolysaccharidosis type IIIB

  2014cited by this paper
• Quantitative dissection and modeling of the NF-κB p100-p105 module reveals interdependent precursor proteolysis.

  2014cited by this paper
• Modulation of endoplasmic reticulum (ER) stress-induced autophagy by C/EBP homologous protein (CHOP) and inositol-requiring enzyme 1α (IRE1α) in human colon cancer cells.

  2014cited by this paper
• Proteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy

  2014cited by this paper
• Neuronal-specific overexpression of a mutant valosin-containing protein associated with IBMPFD promotes aberrant ubiquitin and TDP-43 accumulation and cognitive dysfunction in transgenic mice.

  2013cited by this paper
• The p97-UFD1L-NPL4 Protein Complex Mediates Cytokine-Induced IκBα Proteolysis

  2013cited by this paper
• Covalent and allosteric inhibitors of the ATPase VCP/p97 induce cancer cell death.

  2013cited by this paper
• Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.

  2013cited by this paper
• Structure–Activity Relationship Study Reveals ML240 and ML241 as Potent and Selective Inhibitors of p97 ATPase

  2013cited by this paper
• ER Stress Activates NF-κB by Integrating Functions of Basal IKK Activity, IRE1 and PERK

  2012cited by this paper
• Circumventing cancer drug resistance in the era of personalized medicine.

  2012cited by this paper
• The Cdc48 machine in endoplasmic reticulum associated protein degradation.

  2012cited by this paper
• Emerging functions of the VCP/p97 AAA-ATPase in the ubiquitin system

  2012cited by this paper
• Reversible inhibitor of p97, DBeQ, impairs both ubiquitin-dependent and autophagic protein clearance pathways

  2011cited by this paper
• Nrf2 and NF-κB modulation by sulforaphane counteracts multiple manifestations of diabetic neuropathy in rats and high glucose-induced changes.

  2011cited by this paper
• Autophagy induction and CHOP under-expression promotes survival of fibroblasts from rheumatoid arthritis patients under endoplasmic reticulum stress

  2010cited by this paper
• Sulforaphane suppresses TNF-alpha-mediated activation of NF-kappaB and induces apoptosis through activation of reactive oxygen species-dependent caspase-3.

  2009cited by this paper
• Effect of lumiracoxib on proliferation and apoptosis of human nonsmall cell lung cancer cells in vitro.

  2008cited by this paper
• Synergistic effect of combining paeonol and cisplatin on apoptotic induction of human hepatoma cell lines

  2007cited by this paper
• Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells.

  2005cited by this paper
• Translational Repression Mediates Activation of Nuclear Factor Kappa B by Phosphorylated Translation Initiation Factor 2

  2004cited by this paper
• Activating Transcription Factor 3 Is Integral to the Eukaryotic Initiation Factor 2 Kinase Stress Response

  2004cited by this paper
• Roles of CHOP/GADD153 in endoplasmic reticulum stress

  2004cited by this paper
• NF-κB transcription factor induces drug resistance through MDR1 expression in cancer cells

  2003cited by this paper
• Phosphorylation of the alpha subunit of eukaryotic initiation factor 2 is required for activation of NF-kappaB in response to diverse cellular stresses.

  2003cited by this paper
• Basal levels and patterns of anticancer drug-induced activation of nuclear factor-kappaB (NF-kappaB), and its attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cells.

  2002cited by this paper
• Repression of GADD153/CHOP by NF-κB: a possible cellular defense against endoplasmic reticulum stress-induced cell death

  2001cited by this paper

• Regulation of ER-Resident Transcription Factor NFE2L1 in HEK293 Cells.

  2026cites this paper
• Plant Foods and Their Bioactives as Dietary Enhancers for Colon Cancer Treatment with 5-Fluorouracil

  2025cites this paper
• Antitumor Efficacy of 1,2,4-Triazole-Based VCP/p97 Allosteric Inhibitors.

  2025cites this paper
• Mechanism of allosteric inhibition of human p97/VCP ATPase and its disease mutant by triazole inhibitors

  2024cites this paper
• Comprehensive Insights Into the Combinatorial Uses of Selected Phytochemicals in Colorectal Cancer Prevention and Treatment: Isothiocyanates, Quinones, Carotenoids, and Alkaloids

  2024cites this paper
• Harnessing Sulforaphane Potential as a Chemosensitizing Agent: A Comprehensive Review

  2024cites this paper
• Exploring in vivo combinatorial chemo-immunotherapy: Addressing p97 suppression and immune reinvigoration in pancreatic cancer with tumor microenvironment-responsive nanoformulation.

  2024cites this paper
• An innovative nanoformulation utilizing tumor microenvironment-responsive PEG-polyglutamic coating and dynamic charge adjustment for specific targeting of ER stress inducer, MicroRNA, and immunoadjuvant in pancreatic cancer: In vitro investigations.

  2023cites this paper